Müller-Vahl, Kirsten R. http://orcid.org/0000-0002-7181-7419
Szejko, Natalia http://orcid.org/0000-0001-6160-9221
Verdellen, Cara http://orcid.org/0000-0002-3436-6903
Roessner, Veit http://orcid.org/0000-0002-1873-7081
Hoekstra, Pieter J.
Hartmann, Andreas http://orcid.org/0000-0002-0335-984X
Cath, Danielle C. http://orcid.org/0000-0001-9539-4118
Funding for this research was provided by:
Medizinische Hochschule Hannover (MHH)
Article History
Received: 8 March 2021
Accepted: 19 June 2021
First Online: 10 July 2021
Declaration
:
: KMV has received financial or material research support from EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978) DFG: GZ MU 1527/3-1 and GZ MU 1527/3-2, BMBF: 01KG1421, National Institute of Mental Health (NIMH), Tourette Gesellschaft Deutschland e.V. Else-Kröner-Fresenius-Stiftung, GW pharmaceuticals, Almirall Hermal GmbH, Abide Therapeutics, and Therapix Biosiences. She has received consultant's honoraria from Abide Therapeutics, Boehringer Ingelheim International GmbH, Bionorica Ethics GmbH, CannaMedical Pharma GmbH, Canopy Grouth, Columbia Care, CTC Communications Corp., Demecan, Eurox Deutschland GmbH, Global Praxis Group Limited, IMC Germany, Lundbeck, Sanity Group, Stadapharm GmbH, Synendos Therapeutics AG, and Tilray. She is an advisory/scientific board member for CannaMedical Pharma GmbH, Bionorica Ethics GmbH, CannaXan GmbH, Canopy Growth, Columbia Care, IMC Germany, Leafly Deutschland GmbH, Sanity Group, Syqe Medical Ltd., Therapix Biosciences Ltd., and Wayland Group. She has received speaker’s fees from Aphria Deutschland GmbH, Almirall, Cogitando GmbH, Emalex, Eurox Deutschland GmbH, Ever pharma GmbH, Meinhardt Congress GmbH, PR Berater, Spectrum Therapeutics GmbH, Takeda GmbH, Tilray, Wayland Group. She has received royalties fromDeutsches Ärzteblatt, Der Neurologie und Psychiater, Elsevier, Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, and Kohlhammer. She served as a guest editor for Frontiers in Neurology on the research topic “The neurobiology and genetics of Gilles de la Tourette syndrome: new avenues through large-scale collaborative projects”, is an associate editor for “Cannabis and Cannabinoid Research” and an Editorial Board Member of “Medical Cannabis and Cannabinoids” und “MDPI-Reports” and a Scientific board member for “Zeitschrift für Allgemeinmedizin”. NSZ has no conflicts to declare. DC has received financial support from EU (FP7-HEALTH-2011 No. 278367; FP7-PEOPLE-2012-ITN No. 316978), from VCVGz, and from Tourette Association of America. AH has received financial or material research support from the Association Française pour le syndrome de Gilles de la Tourette (AFSGT). He has received consultant's honoraria from Lundbeck and Noema Pharma. VR has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals, lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma, and support for research from Shire Pharmaceuticals and Novartis. He has carried out clinical trials in cooperation with the Novartis, Shire, Servier and Otsuka companies. PJH has received a honorarium for an advisory board meeting of Shire. NSZ and CV have no conflicts to declare.